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Myeloid sarcoma (MS) is a rare variant of myeloid malignancy.
Condition was described ﬁrst by Burns [1], named as chloroma in
1853 [2] after almost 40 years, but association between MS and
leukemia was recognized by Dock and Warthin [3] and term
granulocytic sarcoma was suggested by Rappaport in 1967 [4]. The
World Health Organization has classiﬁed MS into 3 main types,
depending on the degree of maturation; (i) blastic type, mainly
composed of myeloblasts (ii) immature type, composed of myelo-
blasts and promyelocytes and (iii) differentiated type composed of
promyelocytes and more mature myeloid cells [5]. It manifests as
an extra-medullary tumor composed of myeloblasts and myeloid
precursors with varying degrees of differentiation, and moreAbbreviations: MS, Myeloid Sarcoma; AML, Acute myeloid leukemia; WHO,
World Health Organization; CD, Cluster of Differentiation; MPO, Myeloperoxidase;
OOGS, Orbito-ocular granulocytic sarcoma; CNS, Central nervous system; EM,
Extramedullary.
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diagnosis for extramedullary proliferation of myeloid lineage blasts
occurring anywhere in the body. The most common sites are the
lymph nodes, skin and bones, and less often the orbita and the
central nervous system. We describe a patient with AML with Auer
rods (Myeloid Sarcoma according to the WHO classiﬁcation) pre-
senting with two separate MS involvements including the orbita
and posterior mediastinal region.2. Case report
A 7-year-old female was admitted to our clinic with progressive
swelling in the right periorbital region over the previous 7 days. Her
symptoms were fever, frontal headache and weakness. Physical
examination revealed pallor and mild proptosis of the right eye
with restricted eye movement. The liver was palpable 1 cm below
the right costal margin and the spleen 1 cm below the left costal
margin. Complete blood count revealed hemoglobin 7.3 g/dL, leu-
kocytes 10,530/ml and platelets 62,000/ml. Peripheral blood smear
revealed 30% neutrophils, 25% monocytes, 1% basophils, 34% lym-
phocytes and 10% blast cells with Auer rods. Chest X-ray showed an
opacity in the posterior upper zone of the right lung. Bone marrow
aspiration revealed 5% myelocytes, 3% monoblasts, 31% myelo-
blasts, 27% polymorphonuclear leucocytes, 21% lymphocytes, 4%
normoblasts, 2% monocytes, and 5% metamyelocytes. Myeloblasts
exhibited Auer rods and hypogranulation. Positive parameters of
ﬂow cytometric (FCM) analysis of the bone marrow were Cluster of
Differentiation (CD) 45 (95.38%), CD45 þ CD4 (95.38%), CD13
(61.25%), CD45 þ CD34 (55.93%), CD38 (91.74%), CD15 þ CD117
(73.45%), CD45 þ HLA-DR (95.38%), cCDTdt (53.62%), and myelo-
peroxidase (MPO) (99.52%).
AML was diagnosed on the basis of bone marrow aspiration
ﬁndings and bone marrow biopsy which showed young myeloid
cell hyperplasia and myeloblasts. Immunohistochemical staining of
bonemarrow biopsy revealed positivity of myeloperoxidase and CD
13 monoclonal stain. Karyotype analysis revealed a 46, XX chro-
mosome pattern. Cerebrospinal ﬂuid analysis was negative for
myeloid leukemia cells. Orbital magnetic resonance imaging (MRI)
revealed a 10  24 mm mass lesion in the lateral rectus muscle of
the right orbita (Fig. 1). Computerized tomography (CT) of the chestlogy Oncology Chapter of Indian Academy of Pediatrics. This is an open access article
Fig. 1. Orbital MR showing a 10  24 mm mass lesion in the lateral rectus muscle of
the right orbita.
Fig. 3. Hematoxylin and eosin staining of a MS. Diffüz inﬁltration of round, small
malignant neoplastic cells. The neoplastic cells inﬁltrated the skeletal muscles. Original
magniﬁcation  200).
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T4. At the T2 level, the lesion extended to the right paravertebral
soft tissue in the form of a dumbbell tumor. Two homogenized
masses were observed at the left T4-5 levels with a diameter of
19  5 mm and at the T7 level with a diameter of 26  7 mm. No
destruction of the adjacent bone was observed (Fig. 2a). CT-guided
tissue biopsy was performed at the site of the paravertebral lesion.
Immunohistochemical staining of tumor cells revealed MPO (þ),
CD68 (þ), CD34 (þ), CD13 (þ), CD56 focal (þ), and lysosome (þ)
(Fig. 3). Based on these ﬁndings, the patient was diagnosed withMS
with comorbid AML. AML BFM 2004 was administered. InductionFig. 2. a: Computerized tomography of the chest showing a mass lesion extending to
the right paravertebral soft tissue in the form of a dumbbell tumor. b: Computerized
tomography of the chest after treatment.chemotherapy included cytarabine (100 mg/m2/d as a 48 h-ıv-
infusion day 1 starting in the am until day 3 in the am), cytarabine
(100 mg/m2/d bid as a 30 min-iv-infusion, day 3 am until day 8 am,
total 8 doses), idarubicin (12 mg/m2/d iv, day 3, 5, 7, prior to
cytarabine, 120 min-iv-infusion), etoposide-phosphate (150 mg/
m2/d iv, days 6e8, prior to 8.-10.-12. cytarabine dose, as a 1 h-iv-
infusion), cytarabine intrathecally with age-dependent dosage on
day 1 and day 8. Following the induction cycle of chemotherapy, no
mass was observed in CT of the chest (Fig. 2b) and no blasts were
observed on bone marrow smear. The patient is currently being
monitored at another center.3. Discussion
MS is seen in 1e5% of all AML cases. It may occur alone or
concurrently with myelodysplastic syndrome, myeloproliferative
disease or AML. Montoro J et al. reviewed a case in which MS
preceded a diagnosis of AML by months or years [6]. Our case was
compatible with blastic type MS concurrent with AML.
MS is more commonly encountered in childhood AML than in
adults. Ohanian et al. reportedMS in 9% of AML cases of all ages and
in 40% of childhood AML cases. The signs and symptoms of MS are
related to the pressure effect of the sarcoma mass on adjacent
structures [7]. Orbital involvement orbito-ocular granulocytic sar-
coma (OOGS) as an initial manifestation of AML is less common.
Most cases present with unilateral proptosis, and only a few case
reports have documented of bilateral orbital involvement as an
initial manifestation of AML [8]. Patients may present with painful
proptosis and restricted eye movements.
Clinical and imaging features of OOGS have been described by
Bidar et al. [8] OOGS may include lacrimal gland enlargement,
conjunctival mass and even uveal inﬁltration. Our case presented
with progressive swelling in the right periorbital region.
Myeloid sarcomas are commonly located in the bone, perios-
teum, soft tissues of head and neck region, skin and orbita. Rarely,
they may be located in the intestine, mediastinum, pleura, perito-
neum, biliary tract, breast, uterus and ovaries [7]. Involvement of
the central nervous system (CNS) is rare, and spinal cord
compression by MS in the form of a dumbbell tumor is even rarer
[9]. Our patient presented with AML with two separate MS in-
volvements including the orbita and posterior mediastinal region.
A mass in the right paraspinal soft tissue extended to the right
paravertebral region, but there was no spinal cord compression.
Neuroblastoma, ganglioneuroblastoma, ganglioneuroma, neuroﬁ-
broma, and pheochromocytoma causing posterior mediastinal
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the posterior mediastinum. Our patient's urine test was negative
for vanilmandelic acid and homovanillic acid. When MS occurs in
the setting of previously or concurrently diagnosed AML, a tissue
sample is needed for accurate diagnosis. Appropriate immunohis-
tochemical staining in these cases is particularly essential in order
to establish deﬁnitive diagnosis. Imaging investigation in our case
revealed posterior mediastinal MS, which was veriﬁed by tissue
biopsy. Peripheral blood and bone marrow aspirate examinations
conﬁrmed the diagnosis of AML.
Bakst et al. [10] reported that the molecular mechanisms un-
derlying EM involvement are not well deﬁned but recent immu-
nophenotyping, cytogenetic, and molecular analysis are beginning
to provide some understanding. A variety of chromosomal abnor-
malities have been reported in patients with AML with EM
involvement. The t(8;21) translocation is the most commonly re-
ported cytogenetic abnormality associated with EM involvement,
both at presentation and at relapse. In children, it has been asso-
ciated with orbital MS. The inv(16) is another cytogenetic abnor-
mality with a higher incidence of EM involvement, particularly in
the abdomen. Molecularly, t(8;21) and inv(16) result in the AML1/
ETO44 (RUNX1/RUNX1T1) and CBF_/MYH1145 fusion genes,
respectively, which carry a relatively favorable prognosis. Other
reported abnormalities in MS include t(9;11), 49 del(16q),
50 t(8;17), 51 t(8;16), 52 and t(1;11). Recent systematic ﬂuores-
cence in situ hybridization analysis on MS samples detected several
chromosomal aberrations, including monosomy 7, trisomy 4, tri-
somy 8, trisomy 11, del(5q), and del(20q), among others previously
mentioned [10]. We only conducted ﬂuorescence in situ hybridi-
zation analysis of bone marrow for del 5q31, del 20q12, del 7q31,
trisomy 8 because of limited analysis of cytogenetics laboratory.
It is still unclear whether MS confers a poorer prognosis in pa-
tients with AML than AML alone. Some case reports, however, have
demonstrated survival rates similar to that of AML in both adult and
pediatric populations, with 3- and 5-year survival rates of 30% and
21%, respectively [5,11]. Regardless of whether or not it is associated
with systemic AML, MS is treated with an aggressive chemotherapy
regimen similar to that employed in treating systemic AML [11].
Chemotherapy is the mainstay of treatment, but allogeneic bone
marrow transplantation from a matched family donor still remainsthe best long-term option providing remission-free survival for
most patients.
The simultaneous presence of two extramedullary involvements
in both orbital and posterior mediastinal masses in childhood AML
is very rare. Granulocytic sarcoma should be considered at differ-
ential diagnosis of posterior mediastinal mass in patients with or
without AML because granulocytic sarcoma is not always associ-
ated with AML blast cells at bone marrow inﬁltration [12]. Granu-
locytic sarcoma should be remembered in patients with AML
presenting with a mass anywhere in the body.Conﬂict of interest
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